Cortagen

Origin and Structure

Cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro (AEDP), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of Russian short peptide bioregulators — a class of 2–4 residue peptides reverse-engineered from natural organ extracts in an attempt to identify the minimal signaling fragments responsible for each extract's tissue-specific activity.

Cortagen's parent preparation is Cortexin, a polypeptide extract of calf cerebral cortex used in Russian neurology since the 1980s. Khavinson's group analyzed Cortexin's amino acid composition and tested candidate short sequences for matching transcriptional activity; AEDP emerged as the lead candidate for the brain-cortex bioregulator role.

Mechanism of Action

The Khavinson school proposes that short peptide bioregulators enter cells, translocate to the nucleus, and bind specific promoter regions of genes characteristic of the tissue from which the parent extract was derived — a model that resembles a simplified transcription-factor-mimetic mechanism. In the case of Cortagen, mouse-heart microarray work published by Khavinson's group reported differential expression of dozens of genes after peptide exposure, an effect profile that the authors interpret as evidence of targeted transcriptional modulation.

Independent mechanistic confirmation of the "short peptide enters the nucleus and binds DNA directly" model is thin outside the Khavinson laboratory's own output. Western peer-reviewed literature generally treats the mechanism as plausible but unresolved — there are few well-controlled binding or structural studies that would nail down target promoters or define the peptide's cellular trafficking.

Claimed Effects

Russian clinical and preclinical literature ascribes several effects to Cortagen, most centered on cortical function:

• Post-stroke cognitive recovery as an adjunct to standard rehabilitation, with reported improvements on attention and memory scales.
• Protection of cortical neurons in models of ischemia and hypoxia.
• Support of peripheral nerve regeneration in traumatic and diabetic neuropathy models.
• Mild nootropic effects in older adults with subjective cognitive complaints.

Clinical Evidence

Cortagen's human data is almost entirely Russian, published in Russian-language journals, with small sample sizes and limited methodological transparency by Western clinical-trial standards. It has been used in Russian clinical neurology for roughly two decades and is positioned as a short-peptide adjunct to — or replacement for — Cortexin. International peer-reviewed validation is essentially absent. Reviewers outside Russia have generally noted that the Khavinson-school peptides produce an interesting and internally consistent body of work that nonetheless remains unreplicated by independent groups in adequately powered trials.

Practical Considerations

Research and Russian clinical protocols typically use 1–5 mg per dose, administered intranasally or by intramuscular injection, for courses of 10–20 days. Intranasal dosing relies on the same olfactory-to-CNS transit invoked for Semax and other Russian peptides. Cortagen is not available through FDA-regulated channels in the United States and reaches Western users primarily through research-chemical suppliers, with the quality-control caveats typical of that market.

For readers exploring this peptide class more broadly, see our Pinealon reference (a related Khavinson tripeptide with pineal/cognitive focus) and Epithalon (the telomerase-modulating flagship of the family).

Safety and Regulatory Status

Cortagen has a generally benign adverse-event profile in Russian clinical use — mild injection-site reactions, occasional headache, rare sleep disturbance. No serious toxicity signals have emerged over two decades of use. It is not FDA-, EMA-, or MHRA-approved for any indication, and it does not appear on the WADA prohibited list. Western regulatory frameworks treat it as an unapproved investigational substance.

The Bottom Line

Cortagen is a representative member of the Khavinson short-peptide school: real Russian clinical exposure, plausible but unresolved mechanism, essentially no Western replication. That combination makes it interesting to researchers and frustrating to evidence-based reviewers in equal measure. Anyone using Cortagen outside a Russian clinical setting should understand that they are relying on a body of evidence the international research community has not independently validated.